EasyBlog

This is some blog description about this site

UNION Initiates Collaboration with Brown University & Rhode Island Hospital to Fight H. pylori

COPENHAGEN, NOVEMBER 13, 2018 – UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders today announced a partnership between Brown University, Rhode Island Hospital and AntibioTx to join forces in the development of a new treatment for Helicobacter pylori. Morten Sommer, CSO at UNION, commented “We are honored and excited to be working with Professor Mylonakis and his group from Brown University to develop a new treatment with great prospects for patients across the world”

H. pylori is one of the world’s most prevalent pathogens and unless treated, colonization usually has lifelong persistence. Most people with H. pylori colonization never experience symptoms, however, each year millions colonized with H. pylori develop gastrointestinal diseases which are also linked to cancer and mortality. Unfortunately, the increase in antibiotic resistance is reducing effective treatment options, hence highlighting the need for new microbiome sparing alternatives.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

UNION therapeutics Announces Successful Phase 1 St...

News